What is the horizon for heart failure with mildly reduced or preserved ejection fraction?

29 August 2026 (18:15 - 18:30)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Professor John J V McMurray

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

3 More presentations in this session

Presentation thumbnail

Canadian recommendations for the use of SGLT2i and mineralocorticoid receptor antagonists in the management of heart failure with mildly reduced or preserved ejection fraction

Doctor M. Davis (Vancouver, CA)

Presentation thumbnail

Canadian recommendations for the use of angiotensin receptor neprilysin inhibitor and GLP-1 RA in the management of heart failure with mildly reduced or preserved ejection fraction

Doctor S. Zieroth (Winnipeg, CA)

Presentation thumbnail

ESC recommendations for the use of SGLT2i, GLP-1 RA, mineralocorticoid receptor antagonists, and angiotensin receptor neprilysin inhibitor in the management of heart failure with mildly reduced or preserved ejection fraction

Professor R. De Boer (Rotterdam, NL)

Access the full session

Session thumbnail

Pharmacologic management of heart failure with mildly reduced or preserved ejection fraction

The Event

Event poster

ESC Congress 2026

29 August 2026 18:15 CET

You may be interested in

Congress Session

New perspectives for the treatment of chronic heart failure

1 September 2024

Congress Presentation

What is on the horizon for HFrEF therapy?

29 August 2025

Congress Presentation

nsMRAs: what emerging trials tell us about the future of heart failure therapy

18 May 2025

Congress Presentation

State-of-the-art lecture on contemporary therapy for HFrEF

28 August 2026

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources